# Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct02305381` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02305381](<https://clinicaltrials.gov/study/NCT02305381>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02305381

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 397 participants.

## Technical summary

Registry record NCT02305381. Randomized; double masking; primary purpose treatment. Start 2014-12-01 (actual); primary completion 2015-11-21 (actual). Results posted on 2018-02-19.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 397 participants (enrolled count; ClinicalTrials.gov record NCT02305381, source copy `cardio:ctgov-nct02305381-2019-06-11`, retrieved 2026-10-26)
- Started: 2014-12-01 (actual) (ClinicalTrials.gov record NCT02305381, source copy `cardio:ctgov-nct02305381-2019-06-11`, retrieved 2026-10-26)
- Primary completion: 2015-11-21 (actual) (ClinicalTrials.gov record NCT02305381, source copy `cardio:ctgov-nct02305381-2019-06-11`, retrieved 2026-10-26)
- Completion: 2015-11-21 (actual) (ClinicalTrials.gov record NCT02305381, source copy `cardio:ctgov-nct02305381-2019-06-11`, retrieved 2026-10-26)
- Results first posted: 2018-02-19 (ClinicalTrials.gov record NCT02305381, source copy `cardio:ctgov-nct02305381-2019-06-11`, retrieved 2026-10-26)
- Countries: United States; Germany; Japan; Puerto Rico; Serbia; Slovakia (ClinicalTrials.gov record NCT02305381, source copy `cardio:ctgov-nct02305381-2019-06-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02305381-2019-06-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes
- Acronym: SUSTAIN™ 5
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): semaglutide
- Intervention (Drug): placebo
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial (`cardio:pubmed-29688502`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials (`cardio:pubmed-29687620`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials (`cardio:pubmed-29766634`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 5a0d72ab8bbda50fa073130afaf874f8610d82b63993bf91a65f82de724b2ff5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
